article thumbnail

STAT+: ‘Learning each other’s language’: FDA, patent office seek to work together to lower drug prices

STAT

But like any pharmaceutical company with an eye toward the future, Celgene continued to seek other ways to wring profits from its development work. Not long after the patent was awarded, the company leveraged federally funded research and began investigating different forms of the compound, called Revlimid.

article thumbnail

STAT+: Pharmalittle: We’re reading about the FDA listing Novo drugs as ‘available,’ pharma layoffs, and more

STAT

Food and Drug Administration drug shortage list as of Wednesday , raising the possibility that the medications could soon be taken off the list entirely, a development that could affect compounding pharmacies and patients relying on compounded drugs, STAT reports. Continue to STAT+ to read the full story…

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Pharmacognosy and Drug Patents: Unveiling Nature’s Medicinal Treasures

Drug Patent Watch

Scientists in this field analyze the chemical compounds in plants, animals, and microorganisms to discover potential new drugs. “Pharmacognosy is the bridge between traditional medicine and modern pharmaceutical science, offering a treasure trove of potential new drugs waiting to be discovered.”

article thumbnail

The Benefits of Integrated CDMO Services: Streamlining Drug Development and Manufacturing

Drug Patent Watch

The Rise of Integrated CDMOs The global biotechnology and pharmaceutical services outsourcing market size was valued at $70.48 billion in 2022 and is expected to grow at a compound annual growth rate of 5.3% from 2023 to 2030.

article thumbnail

Innovative Approaches to Extend the Life of Drug Patents

Drug Patent Watch

Pharmaceutical companies employ various strategies to extend the commercial life and patent protection of successful drugs.

article thumbnail

Axcelead DDP and Astellas partner for targeted protein degrader discovery

Pharmaceutical Business Review

This collaboration aims to leverage Axcelead’s DegLead Platform, an integrated service solution designed for the next generation of small-molecule drug discovery, to support Astellas discovery efforts and contribute to the generation of drug candidate compounds.

article thumbnail

Merck attempts to reduce levels of carcinogenic compounds in diabetes drugs

Pharmafile

Pharmaceutical company Merck has announced that it is attempting to reduce levels of a cancer-causing compound which has been found in its popular type 2 diabetes drugs. The compound, known as nitrosamines or NTTP, often emerges from chemical reactions that can take place throughout the manufacturing process.